<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05020067</url>
  </required_header>
  <id_info>
    <org_study_id>SPLS-IMRT NPC</org_study_id>
    <nct_id>NCT05020067</nct_id>
  </id_info>
  <brief_title>Impact on Xerostomia for Nasopharyngeal Carcinoma Patients Treated With or Without Superficial Parotid Lobe-sparing Intensity-modulated Radiotherapy</brief_title>
  <official_title>Impact on Xerostomia for Nasopharyngeal Carcinoma Patients Treated With or Without Superficial Parotid Lobe-sparing Intensity-modulated Radiotherapy: a Prospective Phase II Clinical Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective phase II clinical randomized controlled study, the purpose of this&#xD;
      study is to assess whether superficial parotid lobe-sparing intensity-modulated radiotherapy&#xD;
      (SPLS-IMRT) can decrease the incidence of xerostomia versus conventional IMRT (C-IMRT) in NPC&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 12, 2018</start_date>
  <completion_date type="Actual">August 17, 2021</completion_date>
  <primary_completion_date type="Actual">November 6, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the incidence of xerostomia</measure>
    <time_frame>12 months</time_frame>
    <description>the incidence of xerostomia at 12m post-RT based on Radiation Therapy Oncology Group (RTOG) criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>xerostomia questionnaire score</measure>
    <time_frame>12 months</time_frame>
    <description>The XQ consisted of 8 specific questions which were listed as follows: difficulty in talking; difficulty in chewing; difficulty in swallowing solid food; frequency of sleeping problems; mouth and throat dryness when eating food; mouth and throat dryness while not eating; frequency of sipping liquids to aid swallowing food; frequency of sipping liquids for oral comfort when not eating.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salivary flow rate</measure>
    <time_frame>12 months</time_frame>
    <description>unstimulated salivary flow rateand stimulated salivary flow rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>locoregional relapse-free survival</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distant metastasis-free survival</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <condition>Radiation-induced Xerostomia</condition>
  <arm_group>
    <arm_group_label>SPLS-IMRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The superficial parotid lobe was contoured as an OAR, and V26 (the percentage volume receiving 26 Gy or more) in the superficial parotid lobe was constrained to be less than 30%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C-IMRT</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The entire parotid gland was delineated as an OAR, and V36 (the percentage volume receiving 36 Gy or more) in the entire parotid gland was constrained to be less than 40%</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>superficial parotid lobe-sparing intensity-modulated radiotherapy</intervention_name>
    <description>The superficial parotid lobe was contoured as an OAR, and V26 (the percentage volume receiving 26 Gy or more) in the superficial parotid lobe was constrained to be less than 30%.</description>
    <arm_group_label>SPLS-IMRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:1) newly diagnosed, histologically confirmed World Health Organization&#xD;
        (WHO) type II-III NPC; 2) stage I-IVa (T1-4 N0-3M0) according to the staging system of the&#xD;
        8th American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC);&#xD;
        3) no prior antitumor therapy; 4) no tumor involvement in salivary gland; 5) no parotid&#xD;
        glands disorder and no history of parotid glands surgery; 6) ages between 18 and 70 years;&#xD;
        7) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, and 8) adequate&#xD;
        organ function Exclusion Criteria: 1) used salivary stimulating or protecting agent; 2)&#xD;
        metachronous or synchronous malignancy; 3) pregnancy or lactation; or 4) severe&#xD;
        comorbidities. The pretreatment evaluation included a complete history and physical&#xD;
        examination, nasopharyngoscopy, chest X-ray, complete blood count, liver and renal&#xD;
        biochemistry, and magnetic resonance imaging (MRI) of the head and neck.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.sysucc.org.cn</url>
    <description>Home Page of Cancer Center, Sun Yat-sen University</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 20, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhao Chong</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Xerostomia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

